Cyclerion Therapeutics, INC 8-K filings

Cyclerion Therapeutics and privately-held Korsana Biosciences announced a definitive merger agreement and a concurrent $380 million private financing to advance Korsana's neurodegenerative disease pipeline, including a lead Alzheimer's program.

Cyclerion Therapeutics announced positive FDA feedback for its lead product candidate, CYC-126, and formed a Clinical Advisory Board, staying on track for a Phase 2 study in Treatment Resistant Depression.

Cyclerion Therapeutics announced a strategic collaboration with Medsteer to enhance its anesthetic delivery platform for CYC-126 in treatment-resistant depression, targeting a Phase 2 study in H2 2026.

Cyclerion Therapeutics is set to receive a $1.0 million milestone payment from Akebia Therapeutics following the initiation of Phase 2 clinical trials for Praliciguat in focal segmental glomerulosclerosis.

Cyclerion Therapeutics has announced a transformational relaunch, securing an exclusive license from MIT to develop therapies for neuropsychiatric disorders, starting with treatment-resistant depression.

Cyclerion Therapeutics, Inc. announced the results of its Annual Meeting of Shareholders held on June 16, 2025, where all director nominees were re-elected, Ernst & Young LLP was ratified as the independent auditor, and executive compensation was approved.

Cyclerion Therapeutics has entered into a sales agreement with Guggenheim Securities to offer and sell up to $20 million of its common stock through an at-the-market offering.

Cyclerion Therapeutics has entered into a stock purchase agreement for a private placement of common stock, raising $1.375 million for general corporate purposes.

Cyclerion Therapeutics has amended its license agreement with Akebia and entered into a license option agreement, generating $1.75 million in near-term revenue and shifting intellectual property responsibilities.

Cyclerion Therapeutics has promoted Regina Graul to Chief Executive Officer, President, and member of the Board of Directors, effective August 7, 2024.

Cyclerion Therapeutics held its annual shareholder meeting on June 14, 2024, where directors were elected and the company's auditor was ratified.

Cyclerion Therapeutics has announced that its 2024 Annual Meeting of Shareholders will be held virtually on June 14, 2024.